Publications by authors named "Hajira Kataike"
Effect of dolutegravir on folate, vitamin B12 and mean corpuscular volume levels among children and adolescents with HIV: a sub-study of the ODYSSEY randomized controlled trial.
J Int AIDS Soc
September 2023
Article Synopsis
- Dolutegravir-based antiretroviral therapy (ART) is recommended for treating children and adolescents with HIV, but earlier studies raised concerns about its potential link to neural tube defects.
- A sub-study was conducted within the ODYSSEY trial in Uganda to assess the impact of dolutegravir on folate and vitamin B12 levels, essential for neural tube development, compared to standard care treatments.
- Results indicated that children on dolutegravir had significantly higher plasma and RBC folate levels at both week 4 and week ≥96 compared to those on standard treatment, suggesting a positive effect of dolutegravir on folate status.
Background: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus alternative antiretroviral therapy.
Methods: This is a secondary analysis of ODYSSEY, an open-label, multicentre, randomised, non-inferiority trial, in which adolescents and children initiating first-line or second-line antiretroviral therapy were randomly assigned 1:1 to dolutegravir-based treatment or standard-of-care treatment.
Article Synopsis
- * Conducted between March and September 2021, the pilot study involved 30 young women aged 18-24 with low adherence to PrEP, offering them peer-delivered support along with regular clinic visits to evaluate feasibility and acceptability.
- * Results indicated high acceptance and completion rates of peer visits, with significant improvements in PrEP adherence; qualitative analysis uncovered positive peer experiences, motivating factors from peer support, and various barriers
Background: The Joint United Nations Programme on HIV/AIDS through the 95-95-95 target requires 95% of people living with HIV (PLHIV) on antiretroviral treatment (ART) to be virally suppressed. Viral Load (VL) non-suppression has been found to be associated with suboptimal ART adherence, and Intensive Adherence Counselling (IAC) has been shown to lead to VL re-suppression by over 70% in PLHIV on ART. Currently, there is data paucity on VL suppression after IAC in adult PLHIV in Uganda.
View Article and Find Full Text PDFBackground: We evaluated the efficacy of a community health worker (CHW)-led intervention in supporting disclosure among adults living with HIV in heterosexual relationships.
Methods: We conducted a quasi-experimental study with 2 arms allocated by geographically determined clusters and adjusted for between-group differences among adults living with HIV in the greater Luwero region of Uganda who had never disclosed their status to their current primary sexual partners. Clusters were allocated to either a CHW-led intervention or a control arm.
Background: Adolescents are lagging behind in the "third 95" objective of the Joint United Nations Program on HIV/AIDS requiring 95% of individuals on antiretroviral therapy (ART) to have viral load (VL) suppression. This study aimed to describe factors associated with viral non-suppression among adolescents in Mbale district, Uganda.
Methods: We conducted a retrospective review of routinely collected HIV programme records.
Background: Timely viral load (VL) testing is critical in the care of pregnant women living with HIV and receiving anti-retroviral therapy (ART). There is paucity of data regarding the Time to First Viral Load (TFVL) testing in resource-limited settings.
Methods: We extracted clinical and VL test data from records of a cohort of ART-naïve pregnant women living with HIV who initiated Option B + and were retained in care between 01 Jan 2015 and 31 Dec 2015.
Background: Viral load (VL) testing is the gold-standard approach for monitoring human immunodeficiency virus (HIV) treatment success and virologic failure, but uptake is suboptimal in resource-limited and rural settings. We conducted a cross-sectional study of risk factors for non-uptake of VL testing in rural Uganda.
Methods: We conducted a cross-sectional analysis of uptake of VL testing among randomly selected people with HIV (PWH) receiving anti-retroviral treatment (ART) for at least 6 months at all eight primary health centers in Gomba district, rural Uganda.